Decrease	O
in	O
c	O
-	O
Myc	O
activity	O
enhances	O
cancer	B-Cell
cell	I-Cell
sensitivity	O
to	O
vinblastine	O
.	O

The	O
c	O
-	O
myc	O
oncogene	O
encodes	O
for	O
a	O
transcriptional	O
factor	O
involved	O
in	O
many	O
cellular	B-Cell
processes	O
such	O
as	O
proliferation	O
,	O
differentiation	O
and	O
apoptosis	O
.	O

According	O
to	O
these	O
different	O
functions	O
,	O
the	O
role	O
of	O
c	O
-	O
Myc	O
protein	O
in	O
cellular	B-Cell
sensitivity	O
to	O
anti	O
-	O
cancer	B-Cancer
drugs	O
is	O
controversial	O
.	O

We	O
defined	O
the	O
role	O
of	O
c	O
-	O
Myc	O
in	O
cancer	B-Cell
cell	I-Cell
sensitivity	O
to	O
vinblastine	O
(	O
VLB	O
)	O
using	O
human	O
colon	B-Cell
cancer	I-Cell
cells	I-Cell
:	O
LoVo	B-Cell
wild	O
-	O
type	O
or	O
transfected	O
with	O
a	O
plasmid	B-Cellular_component
containing	O
the	O
human	O
c	O
-	O
myc	O
gene	O
in	O
antisense	O
orientation	O
(	O
LoVo	B-Cell
-	I-Cell
mycANS	I-Cell
)	O
.	O

Analysis	O
of	O
VLB	O
cytotoxicity	O
demonstrated	O
a	O
3	O
-	O
fold	O
increase	O
in	O
VLB	O
sensitivity	O
in	O
LoVo	B-Cell
-	I-Cell
mycANS	I-Cell
cells	I-Cell
.	O

Comparison	O
between	O
cells	B-Cell
revealed	O
different	O
apoptosis	O
kinetics	O
:	O
accumulation	O
of	O
cells	B-Cell
in	O
sub	O
-	O
G1	O
phase	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
cleavage	O
occurred	O
earlier	O
in	O
LoVo	B-Cell
-	I-Cell
mycANS	I-Cell
.	O

Then	O
,	O
we	O
demonstrated	O
a	O
mitochondrial	B-Cellular_component
membrane	I-Cellular_component
potential	O
disruption	O
followed	O
by	O
cytochrome	O
c	O
release	O
that	O
indicates	O
the	O
involvement	O
of	O
mitochondria	B-Cellular_component
in	O
this	O
apoptotic	O
signaling	O
pathway	O
.	O

This	O
earlier	O
apoptosis	O
was	O
accompanied	O
by	O
a	O
Bcl	O
-	O
2	O
decrease	O
and	O
a	O
p53	O
increase	O
.	O

In	O
conclusion	O
,	O
the	O
decrease	O
in	O
c	O
-	O
Myc	O
expression	O
enhanced	O
the	O
VLB	O
sensitivity	O
,	O
triggering	O
earlier	O
apoptosis	O
through	O
induction	O
of	O
the	O
intrinsic	O
pathway	O
.	O

Thus	O
,	O
c	O
-	O
myc	O
induction	O
is	O
a	O
resistance	O
factor	O
and	O
our	O
findings	O
suggest	O
that	O
tumors	B-Cancer
carrying	O
low	O
levels	O
of	O
c	O
-	O
Myc	O
protein	O
could	O
be	O
more	O
responsive	O
to	O
vinca	O
alkaloids	O
treatment	O
.	O

Moreover	O
,	O
the	O
downregulation	O
of	O
c	O
-	O
myc	O
oncogene	O
by	O
an	O
antisense	O
strategy	O
might	O
represent	O
a	O
useful	O
goal	O
for	O
improving	O
the	O
efficacy	O
of	O
this	O
anti	O
-	O
neoplastic	B-Cancer
drug	O
family	O
.	O

